Dhananjay Sinha of Emkay Global Financial Services told CNBC-TV18, “After the sharp correction that has been happening over the last one year largely to do with the USFDA observations, etc and I think there has been a sharp correction that has happened, so I think that part is actually fading out as of now. Within the pharmaceutical space, what we have seen is that pharmaceutical companies, smallcap pharmaceutical or midcap pharmaceutical companies who had lesser exposure to US and more exposure to other continents, they were actually outperforming.” “However, going forward it does appear that the sense we are getting is that the concern on the US regulatory observations, etc is sort of fading out and I think people have found value over there. Aurobindo Pharma has generally been doing well. It has escaped many of these regulatory concerns, so Aurobindo has been our top pick for many years. It continues to be so and I think that has been doing well. So, that is one of our top pick,” he added.